Malignant Liver Tumours: Basic Concepts and Clinical Management

F. Berr, J. Bruix, J. Hauss, Ch. Wittekind, J. Wands (Herausgeber)

Buch | Hardcover

224 Seiten

2002 | 2003 ed.
Springer (Verlag)
978-0-7923-8779-4 (ISBN)

Titel ist leider vergriffen;
keine Neuauflage

Artikel merken

Hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC), both increasing in incidence, have become a major topic of basic and clinical research as well as clinical practice in hepatology. Experts in the field update the current concepts on the carcinogenesis of HCC and CC such as genetic alterations in the pathways of cell cylce and apoptosis regulation, the hypothesis of dedifferentiation of hepatocytes to the malignant phenotype vs that of activation of hepatic progenitor cells incapable of maturation (maturation arrest hypothesis). In spite of an increasing number of genetic alterations described in human HCC as well as cell regulatory pathways tested in experimental HCC models, the key hits causing progression of the cell cycle in imbalance with apoptosis, tissue invasive growth and metastatic potential of cell clones still remain elusive. Very powerful genomic and proteomic techniques are promising insights into the carcinogenesis of liver malignancies that will allow more efficient therapeutic strategies.

The current concepts on risk profiling, surveillance of risk groups and therapeutic strategies are evidence-based for HCC and less detailed for CC. Surveillance of risk groups improves detection of liver tumours in curable stages. Best strategies for curative treatment of HCC use neoadjuvant antitumour therapies before liver transplantation and a role is emerging for living donor-related liver transplantation. New palliative therapies for HCC are in the experimental stage with biological response modifiers, including angiogenesis inhibitors, and entering phase II clinical trials with the alpha-fetoprotein derived vaccines.

List of Principal Authors. Preface.
Section I: Molecular Oncogenesis of Malignant Liver Tumours. 1. Molecular pathogenesis of hepatocellular carcinoma; D.F. Calvisi, S.S. Thorgiersson. 2. Altered signal transduction in human hepatocellular carcinoma; J.R. Wands. 3. Interactions between cell proliferation and apoptosis in the development and progression of liver tumours; N. Fausto, M.E. Vail, R.H. Pierce, C.C. Franlin, J. Campbell. 4. Invasive and metastatic growth of hepatocellular carcinoma; A. Tannapfel.
Section II: Induction of hepatocellular carcinogenesis. 5. Hepatitis B virus-induced carcinoma; M.-A. Buendia. 6. Hepatitis C virus-induced carcinogenesis; M.A. Gonzalez-Carmona, W.H. Caselmann. 7. Role of progenitor cells in carcinogenesis? T. Roskans, L. Libbrecht. 8. Dysplasia carcinoma sequence? P.P. Anthony.
Section III: Clinical Management of Hepatocellular Carcinoma. 9. Risk groups and preventative strategies; M. Colombo. 10. Hepatocellular carcinoma: pathological indicators of prognosis; G.Y. Lauwers. 11. Clinical staging and indicators of prognosis in patients with hepatocellular carcinoma; J. Bruix. 12. Non-surgical intervention therapies; H.-P. Allgaier, D. Galandi, H.E. Blum.
Section IV: Experimental Approaches to New Therapies for Hepatocellular Carcinoma. 13. Immunotherapeutic strategies against hepatocellular carcinoma; M. Geissler, L. Mohr, H. Blum. 14. Gene therapeutic approaches; S. Kubicka. 15. Combination therapy of hepatocellular carcinoma with biological response modifiers; D. Schuppan, C. Herold, M. Ganslmayer, M. Ocker, E.G. Hahn. 16. Graft versus tumour: suppression of hepatocellular carcinoma growth via induction of oral immune-regulation towards tumour-associated antigens; Y. Ilan.
Section V: Cholangiocarcinoma. 17. Aetiopathogenesis, morpgological features and molecular pathology of cholangiocarcinoma; J. Albores-Saavedra. 18. Cholangiocarcinoma: risk groups and diagnostic strategies; G.J. Gores. 19. Non-surgical palliative treatment for cholangiocarcinoma; F. Berr, K. Caca, J. Mössner, M.-A. E.J. Ortner.
Section VI: Surgical Treatment and Prevention of Recurrence for Hepatocellular Carcinoma. 20. Prevention of recurrence for hepatocellular carcinoma after curative surgery; J.M. Llovet. 21. Surgical treatment for hepatocellular carcinoma: the role of living donor-related liver transplantation; C. Valentín-Gamazo, M. Malagó, C.E. Broelsch.
Index.

Erscheint lt. Verlag	30.11.2002
Reihe/Serie	Falk Symposium ; 127A
Zusatzinfo	224 p.
Verlagsort	Dordrecht
Sprache	englisch
Gewicht	485 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hepatologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
ISBN-10	0-7923-8779-1 / 0792387791
ISBN-13	978-0-7923-8779-4 / 9780792387794
Zustand	Neuware